DTME (dithiobismaleimidoethane)
DTME (dithiobismaleimidoethane)
Thermo Scientific™

DTME (dithiobismaleimidoethane)

Thermo Scientific Pierce DTMEは、スペーサーアームの中央のジスルフィド結合を還元することによってスルフヒドリル基(タンパク質やペプチドシステインなど)間の可逆的な共有結合を実現する、中程度の長さのマレイミド架橋剤です。DTMEの特徴:•反応基:マレイミド(両端詳細を見る
製品番号(カタログ番号)数量
2233550 mg
製品番号(カタログ番号) 22335
価格(JPY)
52,100
Online offer
Ends: 27-Mar-2026
86,900
割引額 34,800 (40%)
Each
お問い合わせください ›
数量:
50 mg
一括またはカスタム形式をリクエストする
Thermo Scientific Pierce DTMEは、スペーサーアームの中央のジスルフィド結合を還元することによってスルフヒドリル基(タンパク質やペプチドシステインなど)間の可逆的な共有結合を実現する、中程度の長さのマレイミド架橋剤です。

DTMEの特徴:

反応基:マレイミド(両端)
以下と反応:スルフヒドリル基
• 長基(13.3A)、切断性、スルフヒドリル基-スルフヒドリル基間架橋剤、マレイミド基と11原子ジスルフィドスペーサーアームで構成
•不水溶性—DMFまたはDMSOで最初に溶解し、水性の反応バッファーを追加


DTT、TCEPまたは他の還元剤を使用して二硫化スペーサーアームを還元することによる切断性
架橋剤アプリケーションガイド - この製品に関する最近の文献参照を検索

関連製品
BMH(ビスマレイミドヘキサン)
研究用途にのみご使用ください。診断目的には使用できません。
仕様
細胞透過性Yes
概要DTME
形状Solid
標識法化学的標識
分子量312.36
PEG化No
製品ラインPierce
数量50 mg
反応性部分マレイミド
出荷条件Ambient
溶解性DMF、DMSO
スペーサーアーム長13.3 Å
水溶性No
化学反応性Sulfhydryl-Sulfhydryl
CleavableBy Thiols
クロスリンカータイプホモ二官能性
フォーマットStandard
製品タイプ架橋剤
スペーサー切断可能、長
Unit SizeEach
組成および保存条件
4℃で乾燥した場所に保存。室温で出荷

よくあるご質問(FAQ)

Can you provide the shelf-life for DTME (dithiobismaleimidoethane)?

DTME (dithiobismaleimidoethane) is covered under our general 1-year warranty and is guaranteed to be fully functional for 12 months from the date of shipment, if stored as recommended. Please see section 8.1 of our Terms & Conditions of Sale (https://www.thermofisher.com/content/dam/LifeTech/Documents/PDFs/Terms-and-Conditions-of-Sale.pdf) for more details.

Find additional tips, troubleshooting help, and resources within our Protein Purification and Isolation Support Center.

引用および参考文献 (5)

引用および参考文献
Abstract
Nedd4-1 and beta-arrestin-1 are key regulators of Na+/H+ exchanger 1 ubiquitylation, endocytosis, and function.
Authors:Simonin A, Fuster D
Journal:J Biol Chem
PubMed ID:20855896
'The ubiquitously expressed mammalian Na(+)/H(+) exchanger 1 (NHE1) controls cell volume and pH but is also critically involved in complex biological processes like cell adhesion, cell migration, cell proliferation, and mechanosensation. Pathways controlling NHE1 turnover at the plasma membrane, however, are currently unclear. Here, we demonstrate that NHE1 undergoes ubiquitylation ... More
The extreme C terminus of the ABC protein DrrA contains unique motifs involved in function and assembly of the DrrAB complex.
Authors:Zhang H, Pradhan P, Kaur P
Journal:J Biol Chem
PubMed ID:20876527
'Two novel regulatory motifs, LDEVFL and C-terminal regulatory Glu (E)-rich motif (CREEM), are identified in the extreme C terminus of the ABC protein DrrA, which is involved in direct interaction with the N-terminal cytoplasmic tail of the membrane protein DrrB and in homodimerization of DrrA. Disulfide cross-linking analysis showed that ... More
Association of Rho-associated protein kinase 1 with E-cadherin complexes is mediated by p120-catenin.
Authors:Smith AL, Dohn MR, Brown MV, Reynolds AB
Journal:Mol Biol Cell
PubMed ID:22031287
The dynamic functional linkage of cadherins with the underlying actin cytoskeleton is tightly regulated to achieve proper cell-cell adhesion. p120-catenin (p120) regulates both cadherin stability and actin dynamics, but the relationship between these two functions remains unclear. Using a novel proteomic approach called reversible cross-link immunoprecipitation, or ReCLIP, we previously ... More
Claudin-2 forms homodimers and is a component of a high molecular weight protein complex.
Authors:Van Itallie CM, Mitic LL, Anderson JM
Journal:J Biol Chem
PubMed ID:21098027
Tight junctions are multiprotein complexes that form the fundamental physiologic and anatomic barrier between epithelial and endothelial cells, yet little information is available about their molecular organization. To begin to understand how the transmembrane proteins of the tight junction are organized into multiprotein complexes, we used blue native-PAGE (BN-PAGE) and ... More
Strategies for stabilizing superoxide dismutase (SOD1), the protein destabilized in the most common form of familial amyotrophic lateral sclerosis.
Authors:Auclair JR, Boggio KJ, Petsko GA, Ringe D, Agar JN
Journal:Proc Natl Acad Sci U S A
PubMed ID:21098299
Amyotrophic lateral sclerosis (ALS) is a disorder characterized by the death of both upper and lower motor neurons and by 3- to 5-yr median survival postdiagnosis. The only US Food and Drug Administration-approved drug for the treatment of ALS, Riluzole, has at best, moderate effect on patient survival and quality ... More